Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verona Pharma Plc ADR (NQ: VRNA )

39.63 -0.27 (-0.68%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verona Pharma Plc ADR

< Previous 1 2 3 4 Next >
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
The market uptrend is under pressure. 
Via Investor's Business Daily
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BTIG Maintains Buy Rating for Verona Pharma: Here's What You Need To Know
Via Benzinga
Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High
The experimental mist reduced the risk of exacerbations in patients by 36%. 
Via Investor's Business Daily
Short Volatility Alert: Verona Pharma plc
On Wednesday, shares of Verona Pharma plc (NASDAQ: VRNA) experienced volatile short activity. After the activity, the stock price went down -0.90% to $9.96. The overall sentiment for VRNA has been... 
Via Benzinga
Tesla, Amazon, Nike, FedEx, Verona Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the green on Tuesday, albeit just marginally higher, ending a four-day losing streak as investors and traders are watching out for a much anticipated year-end rally.... 
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
HC Wainwright Raises Price For This Lung Disease Stock On First Pivotal Readout
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
SINT Stock Alert: What to Know About Sintx Technologies’ Reverse Stock Split
Sintx Technologies (SINT) stock is in the news Tuesday as the company enacted a reverse stock split when markets opened this morning. 
Via InvestorPlace
Why Is Verona Pharma (VRNA) Stock Up 34% Today?
Verona Pharma (VRNA) stock is rising higher on Tuesday after the company released results from a Phase 3 clinical trial. 
Via InvestorPlace
Verona Pharma Stock Garners Investors' Attention After Successful COPD Trial
Via Benzinga
Lucid Is Revving Up, but This Nasdaq Stock Is Jumping Even More
Investors hoped for a rebound in the stock market, but they might have to settle for gains in these two stocks. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Lucid Group, Verona Pharma And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! 
Via InvestorPlace
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small... 
Via Benzinga
Why You Should Invest Microcap Stocks
There’s a misperception in the market that low-priced stocks can move faster than high-priced stocks. 
Via Talk Markets
Earnings Scheduled For November 9, 2022
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
US Stock Futures Signal Higher Start On Wall Street; Bank of America Earnings In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Monday after closing lower in the previous session. The Dow Jones dropped by more than 400 points in the previous session,... 
Via Benzinga
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
The biotech run off a June bottom is great — until you realize you could've netted more. 
Via Investor's Business Daily
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
Upgrades 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.